Analysts Anticipate United Therapeutics Co. (UTHR) Will Announce Quarterly Sales of $384.73 Million

Analysts forecast that United Therapeutics Co. (NASDAQ:UTHR) will announce sales of $384.73 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for United Therapeutics’ earnings, with estimates ranging from $350.20 million to $418.75 million. United Therapeutics reported sales of $370.50 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 3.8%. The firm is scheduled to issue its next quarterly earnings results on Wednesday, April 25th.

According to Zacks, analysts expect that United Therapeutics will report full-year sales of $1.44 billion for the current fiscal year, with estimates ranging from $1.35 billion to $1.57 billion. For the next financial year, analysts forecast that the company will report sales of $1.28 billion per share, with estimates ranging from $1.21 billion to $1.37 billion. Zacks’ sales averages are a mean average based on a survey of research firms that follow United Therapeutics.

How to Become a New Pot Stock Millionaire

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $3.89 earnings per share for the quarter, beating analysts’ consensus estimates of $3.59 by $0.30. The company had revenue of $464.70 million for the quarter, compared to the consensus estimate of $420.55 million. United Therapeutics had a return on equity of 24.41% and a net margin of 24.22%. The company’s quarterly revenue was up 13.6% on a year-over-year basis. During the same period in the previous year, the business earned $4.12 earnings per share.

Several research analysts have recently commented on UTHR shares. ValuEngine raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Tuesday, December 26th. Zacks Investment Research raised United Therapeutics from a “hold” rating to a “buy” rating and set a $160.00 target price on the stock in a report on Monday, January 15th. Wedbush reissued an “outperform” rating and issued a $232.00 target price (up from $213.00) on shares of United Therapeutics in a report on Wednesday, December 27th. Barclays reissued an “underweight” rating and issued a $105.00 target price (down from $115.00) on shares of United Therapeutics in a report on Thursday, February 22nd. Finally, Oppenheimer boosted their target price on United Therapeutics to $180.00 and gave the stock an “outperform” rating in a report on Friday, January 5th. Four investment analysts have rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $136.33.

In related news, CEO Martine A. Rothblatt sold 43,025 shares of the business’s stock in a transaction that occurred on Friday, March 16th. The shares were sold at an average price of $111.11, for a total value of $4,780,507.75. Following the completion of the transaction, the chief executive officer now owns 21,652 shares in the company, valued at approximately $2,405,753.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Martine A. Rothblatt sold 301 shares of the business’s stock in a transaction that occurred on Tuesday, March 20th. The stock was sold at an average price of $110.48, for a total transaction of $33,254.48. Following the completion of the transaction, the chief executive officer now owns 21,652 shares of the company’s stock, valued at approximately $2,392,112.96. The disclosure for this sale can be found here. Insiders sold a total of 174,046 shares of company stock valued at $19,506,251 in the last 90 days. 7.80% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of UTHR. Legal & General Group Plc raised its position in United Therapeutics by 10.5% in the 3rd quarter. Legal & General Group Plc now owns 89,846 shares of the biotechnology company’s stock worth $10,530,000 after purchasing an additional 8,549 shares during the last quarter. Mitsubishi UFJ Trust & Banking Corp raised its position in United Therapeutics by 1.3% in the 3rd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 88,399 shares of the biotechnology company’s stock worth $10,359,000 after purchasing an additional 1,124 shares during the last quarter. Schwab Charles Investment Management Inc. raised its position in United Therapeutics by 4.4% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 150,028 shares of the biotechnology company’s stock worth $17,582,000 after purchasing an additional 6,304 shares during the last quarter. Dimensional Fund Advisors LP raised its position in United Therapeutics by 9.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 798,093 shares of the biotechnology company’s stock worth $93,531,000 after purchasing an additional 71,333 shares during the last quarter. Finally, Envestnet Asset Management Inc. raised its position in United Therapeutics by 496.8% in the 3rd quarter. Envestnet Asset Management Inc. now owns 8,511 shares of the biotechnology company’s stock worth $997,000 after purchasing an additional 7,085 shares during the last quarter.

Shares of UTHR traded up $1.21 on Tuesday, hitting $114.09. The company’s stock had a trading volume of 326,656 shares, compared to its average volume of 438,790. The company has a market capitalization of $4,863.17, a P/E ratio of 10.48 and a beta of 1.33. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.26 and a quick ratio of 3.01. United Therapeutics has a fifty-two week low of $106.30 and a fifty-two week high of $152.55.

WARNING: “Analysts Anticipate United Therapeutics Co. (UTHR) Will Announce Quarterly Sales of $384.73 Million” was first published by Week Herald and is the property of of Week Herald. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://weekherald.com/2018/04/25/analysts-anticipate-united-therapeutics-co-uthr-will-announce-quarterly-sales-of-384-73-million.html.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Get a free copy of the Zacks research report on United Therapeutics (UTHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply